Note 20 — Stock-Based Compensation

The Company’s Amended and Restated 2020 Omnibus Incentive Plan, or “the 2020 Plan”, authorizes grants of stock-based compensation instruments including but not limited to non-qualified stock options, restricted stock awards (“RSAs”) and performance stock unit awards (“PSUs”) to certain employees and non-employee directors of the Company, to purchase or issue up to 2,770,000 shares of the Company's common stock.

Expenses related to the stock-based compensation instruments and Employee Stock Purchase Plan (“ESPP”) are included in “Compensation and employee benefits” and “Other operating expenses” on the Consolidated Statements of Income.

Below are summaries of the recognized and unrecognized stock-based compensation expense by instrument for the periods indicated:

 

 

For the Year Ended December 31,

 

 

2024

 

 

2023

 

 

2022

 

 

 

(In thousands)

 

Recognized compensation expense:

 

 

 

 

 

 

 

 

 

Options

 

$

205

 

 

$

55

 

 

$

1,017

 

RSAs

 

 

2,383

 

 

 

2,729

 

 

 

1,744

 

PSUs

 

 

2,839

 

 

 

912

 

 

 

379

 

ESPP

 

 

728

 

 

 

432

 

 

 

203

 

Total recognized compensation expense

 

$

6,155

 

 

$

4,128

 

 

$

3,343

 

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

 

 

(In thousands)

 

Unrecognized compensation expense:

 

 

 

 

 

 

 

 

 

Options

 

$

1,363

 

 

$

22

 

 

$

52

 

RSAs

 

 

3,197

 

 

 

2,185

 

 

 

2,648

 

PSUs

 

 

2,508

 

 

 

1,544

 

 

 

920

 

ESPP

 

 

376

 

 

 

 

 

 

 

Total unrecognized compensation expense

 

$

7,444

 

 

$

3,751

 

 

$

3,620

 

Weighted average period expected to be recognized (in years)

 

 

 

 

 

 

 

 

 

Options

 

 

2.6

 

 

 

2.7

 

 

 

0.2

 

RSAs

 

 

1.8

 

 

 

1.7

 

 

 

1.6

 

 

(a)
Stock Options

Stock option awards provide for the option to purchase the Company's common stock. The stock options generally vest ratably over a service period of three years from the date of the grant.

The Company uses the Black-Scholes option pricing model to value stock options in determining the stock-based compensation expense. The compensation expense is recognized over the three-year vesting period using the straight-line method. Forfeitures are recognized as they occur. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant. The expected dividend yield was zero as the Company does not expect to pay dividends in the foreseeable future. Expected volatility is based on average historical volatilities of the Company’s common stock.

The following table presents the assumptions used in the option pricing model at the grant date for options granted during the years ended December 31, 2024, 2023 and 2022:

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

Expected volatility

 

30.00% - 40.00%

 

 

 

28.00

%

 

 

28.00

%

Risk-free interest rate

 

4.60% - 5.33%

 

 

 

1.50

%

 

 

1.50

%

Expected term (in years)

 

 

10.0

 

 

 

10.0

 

 

 

10.0

 

Expected dividends

 

 

 

 

 

 

 

 

 

The table below summarizes stock option activity during the years ended December 31, 2024, 2023 and 2022:

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

 

 

($ in thousands, except per share amounts)

 

Number of shares:

 

 

 

 

 

 

 

 

 

Options outstanding at beginning of year

 

 

752,964

 

 

 

785,000

 

 

 

785,000

 

Granted

 

 

312,808

 

 

 

5,464

 

 

 

 

Exercised

 

 

 

 

 

(37,500

)

 

 

 

Forfeited

 

 

 

 

 

 

 

 

 

Options outstanding at end of year

 

 

1,065,772

 

 

 

752,964

 

 

 

785,000

 

Options exercisable at end of year

 

 

749,321

 

 

 

747,500

 

 

 

523,333

 

Options expected to vest (1)

 

 

316,484

 

 

 

5,464

 

 

 

261,667

 

Weighted average exercise price per share:

 

 

 

 

 

 

 

 

 

Options outstanding at beginning of year

 

$

12.88

 

 

$

12.89

 

 

$

12.89

 

Granted

 

 

18.27

 

 

 

11.68

 

 

 

 

Exercised

 

 

 

 

 

13.00

 

 

 

 

Options outstanding at end of year

 

$

14.46

 

 

$

12.88

 

 

$

12.89

 

Options exercisable at end of year

 

 

12.88

 

 

 

12.89

 

 

 

12.89

 

Options expected to vest (1)

 

 

18.19

 

 

 

11.68

 

 

 

12.89

 

Aggregate Intrinsic value (2):

 

 

 

 

 

 

 

 

 

Options outstanding at end of year

 

$

5,440

 

 

$

3,269

 

 

$

42

 

Options exercisable at end of year

 

 

5,002

 

 

 

3,239

 

 

 

28

 

Options expected to vest (1)

 

 

438

 

 

 

30

 

 

 

14

 

Weighted average remaining contractual life (in years):

 

 

 

 

 

 

 

 

 

Options outstanding at end of year

 

 

6.4

 

 

 

6.1

 

 

 

7.1

 

Options exercisable at end of year

 

 

5.1

 

 

 

6.1

 

 

 

7.1

 

Options expected to vest (1)

 

 

9.6

 

 

 

9.7

 

 

 

7.1

 

(1)
The number of options expected to vest reflects no expected forfeiture.
(2)
The aggregate intrinsic value represents the amount by which the fair value of underlying stock exceeds the “in-the-money” option exercise price.

No stock options were exercised during the years ended December 31, 2024 and 2022. During the year ended December 31, 2023, 37,500 shares were exercised at $13.00 per share, resulting in $0.5 million cash received.

(b)
RSAs

The fair value of RSAs is determined based on the fair market value of the Company’s common shares on the grant date. The estimated fair value of RSAs is amortized as an expense over the three-year requisite service period. The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period.

The table below summarizes restricted stock award activity during the years ended December 31, 2024, 2023 and 2022:

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

 

 

Employee

 

 

Non-Employee Director

 

 

Total

 

 

Employee

 

 

Non-Employee Director

 

 

Total

 

 

Employee

 

 

Non-Employee Director

 

 

Total

 

Number of shares:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unvested at beginning of year

 

 

409,137

 

 

 

61,276

 

 

 

470,413

 

 

 

445,250

 

 

 

48,889

 

 

 

494,139

 

 

 

480,000

 

 

 

26,511

 

 

 

506,511

 

Granted

 

 

195,164

 

 

 

15,939

 

 

 

211,103

 

 

 

198,137

 

 

 

31,629

 

 

 

229,766

 

 

 

125,250

 

 

 

31,215

 

 

 

156,465

 

Vested

 

 

(248,796

)

 

 

(29,785

)

 

 

(278,581

)

 

 

(234,250

)

 

 

(19,242

)

 

 

(253,492

)

 

 

(160,000

)

 

 

(8,837

)

 

 

(168,837

)

Unvested at end of year

 

 

355,505

 

 

 

47,430

 

 

 

402,935

 

 

 

409,137

 

 

 

61,276

 

 

 

470,413

 

 

 

445,250

 

 

 

48,889

 

 

 

494,139

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average grant date fair value per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unvested at beginning of year

 

$

9.39

 

 

$

9.31

 

 

$

9.38

 

 

$

8.61

 

 

$

9.72

 

 

$

8.72

 

 

$

7.04

 

 

$

10.75

 

 

$

7.23

 

Granted

 

 

15.93

 

 

 

17.88

 

 

 

16.08

 

 

 

10.00

 

 

 

9.01

 

 

 

9.86

 

 

 

12.63

 

 

 

9.13

 

 

 

11.93

 

Vested

 

 

8.61

 

 

 

9.57

 

 

 

8.71

 

 

 

8.42

 

 

 

9.87

 

 

 

8.53

 

 

 

7.04

 

 

 

10.75

 

 

 

7.23

 

Unvested at end of year

 

$

13.52

 

 

$

12.03

 

 

$

13.35

 

 

$

9.39

 

 

$

9.31

 

 

$

9.38

 

 

$

8.61

 

 

$

9.72

 

 

$

8.72

 

(c)
PSUs

In February 2022, the Company began granting PSUs to certain employees, including named executive officers under the 2020 Plan. PSUs will vest based on the achievement of predetermined performance goals over performance periods determined by the Compensation Committee. PSUs are subject to forfeiture until predetermined performance conditions have been achieved. The Company recognizes share-based compensation expense for PSUs on a straight-line basis over the requisite service period of the award when it is probable that the performance conditions will be achieved. Compensation expense for PSUs with financial performance measures is measured using the fair value at the date of grant and recorded over each vesting period and may be adjusted over the vesting period based on interim estimates of performance against the pre-set objectives. The granted PSUs represent 100% of the original target award amounts vesting eligibility is based on performance and service conditions of distinct three-year service periods for each award. Accordingly, the number of shares issued at the end of any performance period could range between 0% and 200% of the original target award amount.

A summary of the PSU activity for the years ended December 31, 2024, 2023 and 2022 under the 2020 Omnibus Plan is presented below:

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value Per Share

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value Per Share

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value Per Share

 

Outstanding at beginning of year, unvested

 

 

256,387

 

(1)

$

11.05

 

 

 

102,750

 

 

$

12.63

 

 

 

 

 

$

 

Granted

 

 

157,994

 

(1)

 

15.86

 

 

 

153,637

 

 

 

10.00

 

 

 

102,750

 

 

 

12.63

 

Performance adjustment

 

 

102,750

 

 

 

12.63

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at end of year, unvested

 

 

517,131

 

 

$

12.83

 

 

 

256,387

 

 

$

11.05

 

 

 

102,750

 

 

$

12.63

 

 

(1)
The number of PSUs are presented at 100% of the specified target shares.
(c)
ESPP

In July 2022, the Company initiated an ESPP which allows permitted eligible employees to purchase shares of the Company’s common stock through payroll deductions of up to 15% of their eligible compensation, subject to certain limitations. The purchase price of the shares under the ESPP equals 85% of the lower of the fair market value of the Company’s common stock on either the first or last trading day of each six-month offering period. As of December 31, 2024, a total of 415,727 shares have been issued under the ESPP with 174,595, 167,123 and 74,009 shares issued during the years ended December 31, 2024, 2023 and 2022, respectively.

Compensation expense for the ESPP is calculated as of the beginning of the offering period as the fair value of the employees’ purchase rights utilizing the Black-Scholes option valuation model and is recognized as a compensation expense over the offering period. The table below presents the fair value assumptions used for the periods indicated:

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

Expected volatility

 

28.80% - 67.54%

 

 

 

51.31

%

 

 

49.93

%

Risk-free interest rate

 

5.29% - 5.30%

 

 

 

5.45

%

 

 

2.50

%

Expected term (in years)

 

 

0.5

 

 

 

0.5

 

 

 

0.5

 

Grant date fair value per share

 

$15.79 - $18.06

 

 

$

11.78

 

 

$

11.31

 

Dividend yield

 

 

 

 

 

 

 

 

 

(d)
Treasury Stock

Treasury stock represent shares surrendered to the Company to satisfy tax withholding obligations in connection with the vesting or exercise of stock-based awards. During the years ended December 31, 2024, 2023 and 2022, shares withheld were 94,150, 87,765 and 33,647, respectively, at an average price of $16.46, $9.81 and $13.61 per share, respectively.

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.